MyOme, a Menlo Park, CA-based clinical whole genome platform analysis company, raised $23m in Series B financing.
The round, which brought the total raised to over $36M, was led by Healthcare Venture Partners.
The company intends use the funds to commercialize its clinical whole genome platform technology and clinical reports for health systems.
Premal Shah, PhD is the CEO and Matthew Rabinowitz (PhD), co-founders and chairs MyOme, a platform for clinical whole genome analysis that allows families to assess their risk of inheritable diseases. It is accredited under the Clinical Laboratory Improvement Amendments.